文献速递乳腺癌

基于局部区域复发的T1-2N1M0乳腺癌风险适配术后放疗

[Risk-adapted postmastectomy radiotherapy based on local-regional recurrence for T1-2N1M0 breast Cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2017-01-01

该回顾性研究纳入2413例pT1-2N1M0乳腺癌患者,按5个独立危险因素分为低、中、高危组。低危组放疗与否生存无差异;中危组PSM后放疗改善LRRFS;高危组放疗改善LRRFS和DFS。提示基于风险分层的PMRT可行。

要点

  • 基于年龄、部位、分子分型、pT分期和阳性淋巴结数分层。
  • 低危组PMRT未改善LRRFS、DFS和OS。
  • 中危组PSM后PMRT改善LRRFS,高危组改善LRRFS和DFS。

核心结论

  • pT1-2N1M0乳腺癌根治术后局部区域复发风险可分层,基于风险适配的PMRT可行。
  • 中危和高危患者可能从PMRT获得更好预后,但需扩大样本验证。

研究设计与样本

  • 采用多因素分析和倾向评分配比(PSM)进行综合比较。

主要发现

  • 全组中位随访67.0个月,5年LRRFS、DFS和OS分别为93.8%、85.7%和93.3%,5年LRR为6.1%。
  • 未PMRT患者多因素分析显示年龄、原发灶部位、分子分型、pT分期和阳性淋巴结数目是LRRFS独立因素(均P<0.05)。
  • 低危组(0-1个危险因素,768例)、中危组(2个,690例)、高危组(≥3个,544例)的5年LRRFS、DFS和OS差异均有统计学意义(P<0.001)。
  • 低危和中危组中PMRT与未PMRT的5年LRRFS、DFS和OS差异均无统计学意义(均P>0.05)。
  • 高危组中PMRT与未PMRT的5年LRRFS分别为93.3%和84.3%(P=0.002),DFS分别为79.8%和74.4%(P=0.127),OS分别为86.8%和87.1%(P=0.174)。

关键数值与推荐

  • PSM后低危组PMRT与未PMRT的5年LRRFS、DFS和OS差异均无统计学意义(均P>0.05)。
  • PSM后中危组PMRT与未PMRT的5年LRRFS分别为95.2%和91.0%(P=0.037)。
  • PSM后高危组PMRT与未PMRT的5年LRRFS分别为93.3%和78.5%(P<0.001),DFS分别为79.7%和69.5%(P=0.038),OS分别为86.6%和85.7%(P=0.080)。

临床怎么用

  • 对pT1-2N1M0乳腺癌术后患者,可依据年龄、原发灶部位、分子分型、pT分期和阳性淋巴结数目进行复发风险分层。
  • 低危患者可能可省略PMRT,中危和高危患者可能从PMRT中获益,尤其高危组改善LRRFS和DFS。

局限性

  • 为回顾性研究,需扩大样本量证实结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To establish a risk-adapted postmastectomy radiotherapy strategy based on local-regional recurrence for intermediate-risk breast cancer (T1~2N1M0 stage). Methods: A total of 2413 patients with T1-2N1M0 breast cancer were retrospectively reviewed. Of them, 588 patients (24.4%) received postmastectomy radiotherapy (PMRT), while 1 825 (75.6%) patients did not. A comprehensive comparative study was performed by using multivariable and propensity score-matched (PSM) analyses. Results: The median follow-up time was 67.0 months, the 5-year local region recurrence free-survival (LRRFS), disease-free survival (DFS) and overall survival (OS) were 93.8%, 85.7% and 93.3%, respectively. The 5-year local region recurrence (LRR) was 6.1%. For patients without PMRT, multivariable analysis indicated that age, tumor localization, molecular subtype, pathologic T stage and number of positive lymph node were independent factors for LRRFS (all of P<0.05). Patients with T1-2N1 breast cancer were classified into low-risk group (0-1 risk factor, 768 patients), intermediate-risk group (2 risk factors, 690 patients) and high-risk groups (≥3 risk factors, 544 patients) based on the five independent factors mentioned above. The 5-year LRRFS, DFS and OS were significantly different among the three groups (P<0.001). In low- and intermediate-risk groups, there were no significant differences in LRRFS, DFS and OS of patients who received PMRT or not (P>0.05). In high-risk group, the DFS of patients received PMRT or not were 79.8% and 74.4%, respectively (P=0.127), the OS of them were 86.8% and 87.1%, respectively (P=0.174), and the LRRFS were 93.3% and 84.3%, respectively (P=0.002). After PSM adjustment, no significant differences in LRRFS, DFS and OS were observed between PMRT-received subgroup and no PMRT subgroup of low-risk group (P>0.05). In intermediate-risk group, the LRRFS of patients received PMRT or not were 95.2% and 91.0%, respectively (P=0.037). However, in the high-risk group, the LRRFS, DFS and OS of patients received PMRT were 93.3%, 79.7% and 86.6%, respectively, while those of patients did not receive PMRT were 78.5% (P<0.001), 69.5% (P=0.038) and 85.7% (P=0.080), respectively. Conclusions: The local-regional recurrence risks of patients with pT1-2N1 breast cancer are viable and risk-adapted PMRT is available for them. Better prognoses can be achieved by the patients of intermediate and high-risk group. More samples on this subject are needed to validate the results. 目的: 探讨早期中危(pT1~2N1M0期)乳腺癌根治术后局部区域复发风险分层和放疗选择。 方法: 2 413例pT1~2N1M0期乳腺癌患者中,根治术后放疗(PMRT) 588例(24.4%),未接受PMRT 1 825例(75.6%),应用多因素和倾向评分配比(PSM)分析进行综合比较研究。 结果: 全组患者中位随访时间为67.0个月,其5年无局部区域复发生存率(LRRFS)、无病生存率和总生存率分别为93.8%、85.7%和93.3%,5年局部区域复发率为6.1%。对未接受PMRT的1 825例患者进行局部区域复发风险分层,多因素分析显示,年龄、原发灶部位、分子分型、pT分期和阳性淋巴结数目是影响LRRFS的独立因素(均P<0.05)。以年龄、原发灶部位、分子分型、pT分期和阳性淋巴结数目5个高危因素进行分组,低危组(0~1个危险因素)768例,中危组(2个危险因素)690例,高危组(≥3个危险因素)544例,3组患者的5年LRRFS、无病生存率和总生存率差异均有统计学意义(P<0.001)。在低危组和中危组中,PMRT组和未接受PMRT组患者的5年LRRFS、无病生存率和总生存率差异均无统计学意义(均P>0.05)。在高危组中,PMRT组和未接受PMRT组患者的5年LRRFS分别为93.3%和84.3%(P=0.002),5年无病生存率分别为79.8%和74.4%(P=0.127),5年生存率分别为86.8%和87.1%(P=0.174)。经过PSM调整,低危组中,PMRT组和未接受PMRT组患者的5年LRRFS、无病生存率和总生存率差异均无统计学意义(均P>0.05)。中危组中,PMRT组和未接受PMRT组患者的5年LRRFS分别为95.2%和91.0%(P=0.037)。在高危组中,PMRT组患者的5年LRRFS、无病生存率和总生存率分别为93.3%、79.7%和86.6%,未接受PMRT组分别为78.5%、69.5%和85.7% (P<0.001,P=0.038,P=0.080)。 结论: pT1~2N1M0期乳腺癌患者根治术后具有不同的局部区域复发风险,基于风险分层的PMRT是可行的,中高危患者可能带来生存获益,但需要扩大样本量证实。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li M, Wang SL, Fang H, et al. [Risk-adapted postmastectomy radiotherapy based on local-regional recurrence for T1-2N1M0 breast Cancer]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 29151291. doi:10.3760/cma.j.issn.0253-3766.2017.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。